Pre-existing immunity modulates responses to mRNA boosters
mRNA vaccines have shown high efficacy in preventing severe COVID-19, but breakthrough infections, emerging variants and waning antibody levels have warranted the use of boosters. Although mRNA boosters have been widely implemented, the extent to which pre-existing immunity influences the efficacy of boosters remains unclear. In a cohort of individuals primed with the mRNA-1273 or BNT162b2 vaccines, we observed that lower antibody levels before boost were associated with higher fold-increase in antibody levels after boost, suggesting that pre-existing antibody modulates the boosting capacity of mRNA vaccines. Mechanistic studies in mice show that pre-existing antibodies significantly limit antigen expression and priming of B cell responses after mRNA vaccination. Furthermore, we demonstrate that the relative superiority of an updated Omicron vaccine over the original vaccine is critically dependent on the serostatus of the host. These data demonstrate that pre-existing immunity dictates responses to mRNA vaccination, elucidating specific circumstances when updated SARS-CoV-2 vaccines confer superior protection to original vaccines.
| Errataetall: |
UpdateIn: Cell Rep. 2023 Feb 15;42(3):112167. - PMID 36857186 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2022) vom: 28. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dangi, Tanushree [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 14.02.2024 published: Electronic UpdateIn: Cell Rep. 2023 Feb 15;42(3):112167. - PMID 36857186 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2022.06.27.497248 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343155125 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343155125 | ||
| 003 | DE-627 | ||
| 005 | 20240214232536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.06.27.497248 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM343155125 | ||
| 035 | |a (NLM)35794898 | ||
| 035 | |a (PII)2022.06.27.497248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dangi, Tanushree |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pre-existing immunity modulates responses to mRNA boosters |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Cell Rep. 2023 Feb 15;42(3):112167. - PMID 36857186 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a mRNA vaccines have shown high efficacy in preventing severe COVID-19, but breakthrough infections, emerging variants and waning antibody levels have warranted the use of boosters. Although mRNA boosters have been widely implemented, the extent to which pre-existing immunity influences the efficacy of boosters remains unclear. In a cohort of individuals primed with the mRNA-1273 or BNT162b2 vaccines, we observed that lower antibody levels before boost were associated with higher fold-increase in antibody levels after boost, suggesting that pre-existing antibody modulates the boosting capacity of mRNA vaccines. Mechanistic studies in mice show that pre-existing antibodies significantly limit antigen expression and priming of B cell responses after mRNA vaccination. Furthermore, we demonstrate that the relative superiority of an updated Omicron vaccine over the original vaccine is critically dependent on the serostatus of the host. These data demonstrate that pre-existing immunity dictates responses to mRNA vaccination, elucidating specific circumstances when updated SARS-CoV-2 vaccines confer superior protection to original vaccines | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Sanchez, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Lew, Min Han |e verfasserin |4 aut | |
| 700 | 1 | |a Visvabharathy, Lavanya |e verfasserin |4 aut | |
| 700 | 1 | |a Richner, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Koralnik, Igor J |e verfasserin |4 aut | |
| 700 | 1 | |a Penaloza-MacMaster, Pablo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2022) vom: 28. Juni |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:28 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.06.27.497248 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 28 |c 06 | ||